AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29855175
Drug: ABT-122 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-122 (240 mg every week)
Trial: 24629425
Drug: Afoxolaner (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afoxolaner (oral chewable formulation at a dose of 2.5mg/kg)
Trial: 22831890
Drug: Lidocaine/tetracaine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/tetracaine patch (Rapydan)
Trial: 22831890
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of lidocaine 1%
Trial: 19336497
Drug: 200 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mug extra fine hydrofluoroalkane (HFA) beclometasone dipropionate twice daily
Trial: 10506039
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg taken orally three times daily
Trial: 1667755
Drug: Cyclical transdermal
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical transdermal oestradiol 0.05 mg per day
Trial: 1667755
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine oestrogens 0.625 mg per day
Trial: 7059440
Drug: Commercial slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial slow-release preparation (Slow Lopresor)
Trial: 28423145
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy (BBT) - 8 to 12 weekly 45-minute sessions delivered by master's-level clinicians.
Trial: 24165545
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with adjunctive slow-release dexamethasone implant
Trial: 19056646
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (714 mg/d GTP), 6 capsules per day for 3 weeks
Trial: 10719615
Drug: Sustained-release capsule
RxNorm normalized name: Dilacor 240mg Sustained-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release capsule of UDCA
Trial: 10719615
Drug: Immediate-release preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release preparation of UDCA
Trial: 1540063
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.9% saline solution
Trial: 2881428
Drug: Psychotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy and Drug Treatment
Trial: 30088707
Drug: Compound amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound amino acid plus vitamin E
Trial: 25419768
Drug: No skin
RxNorm normalized name: Aveeno Skin Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No skin treatment (Control group 3)
Trial: 18606965
Drug: Sumatriptan 85
RxNorm normalized name: sumatriptan 85 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 85 mg and naproxen sodium 500 mg (sumatriptan/naproxen)
Trial: 16015049
Drug: Delayed-release propranolol
RxNorm normalized name: propranolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release propranolol (INP) dosed at 10 p.m.
Trial: 1683673
Drug: Amoxicillin trihydrate
RxNorm normalized name: Amoxicillin Trihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin trihydrate
Trial: 6791197
Drug: Ro 11-2465
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 11-2465 (1 mg daily for 3 days, then 3 mg daily for 7 days)
Trial: 6791197
Drug: Ro 11-2465
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 11-2465 (after drug withdrawal)
Trial: 30902690
Drug: Epinephrine administration
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administration <10 min from EMS arrival
Trial: 30902690
Drug: Epinephrine administration
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine administration ≥10 min from EMS arrival
Trial: 25640368
Drug: Prophylactic use
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic use of JiSaiXin (G‐CSF) 150ug per day for three days after chemotherapy (Group A)
Trial: 25640368
Drug: G‐CSF (JiSaiXin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (JiSaiXin) after neutropenia (Group B)
Trial: 22067789
Drug: New tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New tablet formulation containing 0.02 mg ethinylestradiol/3 mg drospirenone/0.451 mg levomefolate calcium
Trial: 22067789
Drug: Ethinylestradiol/drospirenone tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol/drospirenone tablet
Trial: 22067789
Drug: Levomefolate calcium
RxNorm normalized name: Levomefolate Calcium
DrugBank: Levomefolic acid (DB11256)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levomefolate calcium tablet
Trial: 15224204
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment in control clinic for 6 months.
Trial: 9675505
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (CBT) with exposure and response prevention
Trial: 2696997
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg t.i.d. after 7-10 days
Trial: 2696997
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 10 mg diazepam after 3-4 hours
Trial: 524315
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight heparin fraction (intravenous injection)
Trial: 524315
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin fraction (intravenous injection)
Trial: 524315
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin fractions (subcutaneous injection)
Trial: 524315
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin injection (general)
Trial: 524315
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight heparin (general)
Trial: 524315
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (general)
Trial: 24216069
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs at a dose of 3 g/day for 8 weeks
Trial: 12859262
Drug: Isosorbide-5-mononitrate (ISMN),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (ISMN), 10 mg
Trial: 10609625
Drug: Salmeterol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol added to low-dose beclomethasone dipropionate therapy
Trial: 10609625
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the dose of beclomethasone dipropionate
Trial: 8622048
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen for black myeloma patients
Trial: 8622048
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen for white myeloma patients
Trial: 1941055
Drug: 5FU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU plus low-dose leucovorin
Trial: 1941055
Drug: 5FU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU plus high-dose leucovorin
Trial: 1941055
Drug: 5FU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU plus high-dose MTX with leucovorin rescue
Trial: 27164714
Drug: Rotigotine (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (1-3 mg/24 h)
Trial: 15725351
Drug: CXCL10 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCL10 and its receptor CXCR3
Trial: 2026301
Drug: Intravesical lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical lidocaine gel
Trial: 2026301
Drug: Oral emepronium
RxNorm normalized name: emepronium
DrugBank: Emepronium (DB13505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral emepronium bromide
Trial: 28942715
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 100 mcg
Trial: 28942715
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 200 mcg
Trial: 28942715
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray 400 mcg
Trial: 28942715
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate intravenous 50 mcg
Trial: 19308757
Drug: Other determinants
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other determinants (platinum levels, renal function, glutathione transferase genotypes, diabetes mellitus, alcohol use, co-medication)
Trial: 1497158
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg IM
Trial: 10919528
Drug: Meperidine 1
RxNorm normalized name: meperidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 1 mg/kg IM
Trial: 8974721
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 infusion
Trial: 28195950
Drug: Videoconferencing administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Videoconferencing administration of the La Trobe Communication Questionnaire (LCQ)
Trial: 28195950
Drug: In-person administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person administration of the La Trobe Communication Questionnaire (LCQ)
Trial: 27276842
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg (2 ml) intravenous 60-90 minutes before surgery
Trial: 27276842
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml 60-90 minutes before surgery
Trial: 23937657
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric argon plasma treatment for 2 minutes
Trial: 23937657
Drug: Placebo (argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (argon gas) treatment for 2 minutes
Trial: 21320138
Drug: ADX10059 120
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX10059 120 mg b.d.
Trial: 16984929
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of valsartan and captopril
Trial: 7662044
Drug: Acamprosate 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 2.0 g/day (high dose group)
Trial: 7662044
Drug: Acamprosate 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate 1.3 g/day (low dose group)
Trial: 7662044
Drug: Acamprosate groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate groups (both doses)
Trial: 28713032
Drug: Adaptive Disclosure
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Disclosure (AD) therapy
Trial: 25312783
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination therapy with Pre + TAC + CTX
Trial: 25312783
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination therapy with Pre + TAC + MMF
Trial: 25312783
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination therapy with Pre + TAC + LEF
Trial: 25312783
Drug: Triple-combination therapy
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination therapy with Pre + TAC + CTX/MMF/LEF
Trial: 21256669
Drug: Sterile sodium
RxNorm normalized name: Sterile Sodium Chloride
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile sodium chloride (NaCl) 0.9% solution
Trial: 7272177
Drug: Caroxazone treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caroxazone treatment
Trial: 7272177
Drug: Post-treatment (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (after discontinuation of caroxazone)
Trial: 29931594
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 250 mg three times daily
Trial: 25295771
Drug: mHealth technology
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth technology with tailored physical activity prescription targeting changes to daily exercise, sedentary behavior, or both
Trial: 20453709
Drug: GPO-VIR S7
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPO-VIR S7 chewable tablets
Trial: 16077744
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with 1.5 g/kg body weight of a standard amino acid
Trial: 16077744
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine
Trial: 8622024
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m2 and cyclophosphamide 1,250 mg/m2 with filgrastim 5 microG/kg/d
Trial: 8622024
Drug: Paclitaxel administered
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered first
Trial: 8622024
Drug: Cyclophosphamide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide administered first
Trial: 6130038
Drug: Metoprolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (150 mg per day)
Trial: 30553916
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor antagonists (three different types)
Trial: 29598883
Drug: Omega-3 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (1000 mg/day)
Trial: 29598883
Drug: Both omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both omega-3 (1000 mg/day) and vitamin D (1000 IU/day)
Trial: 24837794
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (2 initial days of double maintenance dose)
Trial: 24837794
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose (most recent maintenance dose)
Trial: 19892836
Drug: Mixed meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed meal in diabetic patients (with and without insulin)
Trial: 12035937
Drug: Alprazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.02 mg/kg po at ‐90 min)
Trial: 10591421
Drug: Lactose-free (L-)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-free (L-) formula
Trial: 10591421
Drug: Standard lactose-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lactose-containing (L+) formula
Trial: 2008006
Drug: Amnioinfusion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioinfusion treatment group (n = 19)
Trial: 26955742
Drug: ATP (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP (40 mg/day) for rabbits; ATP (60 mg twice a day) for patients
Trial: 20167591
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not currently using intramuscular interferon beta-1a)
Trial: 16923824
Drug: Subacromial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subacromial infusion of 0.5% bupivacaine (group 1)
Trial: 16923824
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of fentanyl and ketorolac tromethamine (group 2)
Trial: 12142199
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (group II)
Trial: 9466023
Drug: Lidocaine 2%-buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2%-buprenorphine at a rate of 6.3 ml.hr‐1 (2% group, n = 13)
Trial: 9466023
Drug: Lidocaine 6%-buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 6%-buprenorphine at a rate of 2.1 ml.hr‐1 (6% group, n = 15)
Trial: 31629703
Drug: Ezetimibe (Eze)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (Eze) + statins (simvastatin 10 mg, 20 mg, 40 mg, 80 mg)
Trial: 31629703
Drug: Ezetimibe (Eze)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (Eze) + atorvastatin (20 mg, 40 mg)
Trial: 31629703
Drug: Statin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin monotherapy (simvastatin, atorvastatin)
Trial: 27090395
Drug: High-dose resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose resistance training (RT) maintenance intervention
Trial: 27090395
Drug: Low-dose resistance
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose resistance training (RT) maintenance intervention
Trial: 19198698
Drug: Controlled-release fluvoxamine
RxNorm normalized name: fluvoxamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release fluvoxamine (CR)
Trial: 19198698
Drug: Immediate-release fluvoxamine
RxNorm normalized name: fluvoxamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release fluvoxamine (IR)
Trial: 16807626
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (3 times weekly at 60% of one-repetition maximum, 9 resistance exercises, 3 sets of 15 repetitions each)
Trial: 14568830
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of KTP and Nd:YAG lasers
Trial: 8823230
Drug: Bosentan (oral)
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan (oral) at doses of 3, 10, 30, 100, 300, 600, 1200, and 2400 mg
Trial: 8823230
Drug: Bosentan (intravenous)
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan (intravenous) at doses of 10, 50, 250, 500, and 750 mg
Trial: 8823230
Drug: Bosentan (oral)
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan (oral)
Trial: 8823230
Drug: Bosentan (intravenous)
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan (intravenous)
Trial: 7949478
Drug: bath-PUVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bath-PUVA therapy (30-min baths in 0.0003% 8-MOP aqueous solution, 4 times a week)
Trial: 7949478
Drug: oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of 8-MOP
Trial: 3280317
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 40 mg three times daily
Trial: 3540229
Drug: Verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 120 mg three times daily